Skip to main content
. 2017 Sep;187(9):2020–2033. doi: 10.1016/j.ajpath.2017.05.017

Figure 8.

Figure 8

Changes in B-cell profile in vancomycin, ampicillin, metronidazole, and neomycin (VAMN)–treated 564+/+ mice. Splenocytes from VAMN-treated 6-month-old 564+/+, untreated 564+/+, and B6 control mice were stained with antibodies against B220, CD138, GL7, FAS, CD80, CD86, major histocompatibility complex (MHC) II, and CD40, and analyzed by flow cytometry. A: Total percentages of germinal center B cells (B220+FAS+GL7+) and plasma cells (B220−CD138+). B: Expression of CD86, CD80, MHCII, and CD40 on B220+ cells is shown as mean fluorescence intensity (MFI). Statistical analysis was performed using one-way analysis of variance with Tukey's multiple comparison test. Data are expressed as means ± SEM (A and B). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001.